Demographic and genomic information on the study participants
| Sample ID . | Age, y . | Gender/ethnicity . | HLA-A . | HLA-B . | HLA-DRB . | HLA-DQB . | CCR5 coding region . | CCR5 promoter . |
|---|---|---|---|---|---|---|---|---|
| 229 | 35 | M/W | 2, 3 | 0702, 07 | 1, 1 | 0501, 1501 | WT | A/G |
| 233 | 37 | M/W | 2, 3 | 1402, 15 | 4, 13 | 03, 03 | WT | G/G |
| 243 | 41 | M/W | 2301, 24 | 4001, 44 | 4, 7 | 02, 0301 | WT | A/G |
| 244 | 42 | M/W | 0101, 26 | 0801, 55/56 | 13, 7 | 02, 0301 | WT | A/G |
| 249 | 24 | M/W | 24, 3201 | 27, 40 | 4, 13 | 0603, 0302 | WT | A/G |
| 260 | 28 | M/L | 3, 29 | 0702, 44 | 13, 7 | 0603, 03032 | WT | A/A |
| 263 | 30 | M/A | 24, 33 | 4001, 44 | 12, 7 | 02, 0301 | WT | A/A |
| 264 | 36 | M/L | 2, 2 | 44, 51 | 11, 11 | 03, 03 | WT | G/G |
| 277 | 27 | F/W | 24, 68 | 0702, 13 | 1501, 7 | 0602, 0200 | WT | A/G |
| 278 | 53 | M/W | 2, 32 | 4001, 5601 | 4, 4 | 0305, 0302 | WT | G/G |
| 283 | 43 | M/W | 2, 11 | 0702, 51 | 1501, 9 | 05031, 0602 | Δ32 het | A/A |
| 285 | 40 | M/W | 3, 3002 | 15, 18 | 3, 11 | 02, 0301 | Δ32 het | A/G |
| 286 | 31 | M/W | 2501, 3201 | 1401, 5801 | 1501, 13 | 0602, 0301 | WT | G/G |
| 290 | 41 | M/W | 1, 2 | 0801, 4402 | 4, 0301/6 | 0200, 0302 | WT | A/A |
| 303 | 28 | F/W | 2, 11 | 27, 3508 | 11, 7 | 02, 0301 | WT | A/G |
| Sample ID . | Age, y . | Gender/ethnicity . | HLA-A . | HLA-B . | HLA-DRB . | HLA-DQB . | CCR5 coding region . | CCR5 promoter . |
|---|---|---|---|---|---|---|---|---|
| 229 | 35 | M/W | 2, 3 | 0702, 07 | 1, 1 | 0501, 1501 | WT | A/G |
| 233 | 37 | M/W | 2, 3 | 1402, 15 | 4, 13 | 03, 03 | WT | G/G |
| 243 | 41 | M/W | 2301, 24 | 4001, 44 | 4, 7 | 02, 0301 | WT | A/G |
| 244 | 42 | M/W | 0101, 26 | 0801, 55/56 | 13, 7 | 02, 0301 | WT | A/G |
| 249 | 24 | M/W | 24, 3201 | 27, 40 | 4, 13 | 0603, 0302 | WT | A/G |
| 260 | 28 | M/L | 3, 29 | 0702, 44 | 13, 7 | 0603, 03032 | WT | A/A |
| 263 | 30 | M/A | 24, 33 | 4001, 44 | 12, 7 | 02, 0301 | WT | A/A |
| 264 | 36 | M/L | 2, 2 | 44, 51 | 11, 11 | 03, 03 | WT | G/G |
| 277 | 27 | F/W | 24, 68 | 0702, 13 | 1501, 7 | 0602, 0200 | WT | A/G |
| 278 | 53 | M/W | 2, 32 | 4001, 5601 | 4, 4 | 0305, 0302 | WT | G/G |
| 283 | 43 | M/W | 2, 11 | 0702, 51 | 1501, 9 | 05031, 0602 | Δ32 het | A/A |
| 285 | 40 | M/W | 3, 3002 | 15, 18 | 3, 11 | 02, 0301 | Δ32 het | A/G |
| 286 | 31 | M/W | 2501, 3201 | 1401, 5801 | 1501, 13 | 0602, 0301 | WT | G/G |
| 290 | 41 | M/W | 1, 2 | 0801, 4402 | 4, 0301/6 | 0200, 0302 | WT | A/A |
| 303 | 28 | F/W | 2, 11 | 27, 3508 | 11, 7 | 02, 0301 | WT | A/G |
For HLA-DRB, -DQA1, and -DQB1 typing, locus-specific amplicons were chemically denatured and hybridized to nylon membranes with bound sequence-specific oligonucleotide probes (DRB-36 probes, DQA1-12 probes, and DQB1-31 probes, respectively). The resulting probe patterns were interpreted with customized computer software. The CCR5-Δ32 mutation was detected by PCR amplification using fluorescently labeled primers and electrophoresis in 6% acrylamide denaturing gels on the ABI PRISM 373 Automated DNA Sequencer (PE Biosystems, Foster City, CA). The adenine/guanine (AG) CCR5-promoter polymorphism at position -59029 was detected by PCR amplification, BSP1286 I digestion, and 4% NuSiev (FMC Bioproducts, Rockland, ME) 3:1 electrophoresis.
M indicates male; W, white; WT, wild type; L, Latino; A, Asian; F, female; and Δ32 het, heterozygous for the CCR5 Δ32 mutation.